Developing scalable and modular technologies for continuous biopharmaceutical production

The existing biopharmaceutical manufacturing paradigm is poorly suited to produce biologic drugs on demand at a point-of-care. Generally, commercial-scale manufacturing using fed-batch cultivation and fixed infrastructure is concentrated in developed nations and results in process cycle times of weeks or months. Coupled with the complex logistical challenges associated with continuous 'plant-to-patient' cold-chains, the geographically biased nature of therapeutic protein production today can limit access to biologic drugs in developing areas of the world. These same logistical hurdles can also hamper the efficient distribution of life-saving protein therapeutics following crises in developed nations. Compounding these issues is the fact that lead times between bioreactor inoculation and patient dosing typically range from 6 to 12 months due to processing and regulatory constraints.

Name thesis:degree_name

Doctoral

Department dc:contributor.department

Massachusetts Institute of Technology. Department of Chemical Engineering

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2018

Author dc:creator

• Mozdzierz, Nicholas J.(Nicholas Joseph)

Advisor dc:contributor.advisor

• Richard D. Braatz and J. Christopher Love.

• Chemical Engineering.

Statement dc:rights

• MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

https://hdl.handle.net/1721.1/121817

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/121817